naratriptan / Generic mfg. - LARVOL DELTA

Ischemic Colitis Reporting Across the Triptan Class: A Cross-Database Analysis With FDA Label Review (ACG 2026) - " We queried the FDA Adverse Event Reporting System (FAERS) and WHO VigiBase on 5/1/2026 for IC reports associated with sumatriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, eletriptan, and frovatriptan... Sumatriptan had the highest absolute IC case volume (FAERS: 87 cases; VigiBase: 114 cases) consistent with its dominant overall reporting volume. Rizatriptan was the only agent with significantly elevated IC reporting proportions in both FAERS (1.76% vs 0.79%, p=0.0007) and VigiBase (0.55% vs 0.31%, p=0.009). Frovatriptan was elevated in FAERS only (4.48% vs 0.85%, p=0.020)."

Review • Cardiovascular • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Migraine

Drugs for acute treatment of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparison table: Triptans. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Integration of Mendelian Randomization and FAERS Database Analysis Reveals the Association Between Ergotamine and Aortic and Mitral Valve Diseases. (PubMed, J Cardiovasc Pharmacol) - "Molecular docking revealed that ergotamine and fosfomycin exhibited the highest binding affinities to AGK and TLE5, respectively...For further validation, naratriptan and aztreonam were employed as control drugs...After adding Ly294002 (inhibitor of PI3K-Akt), the western blot results showed that AGK promoted the fibrosis of aortic and mitral interstitial cells via PI3K-Akt signaling pathway. In conclusion, ergotamine may contribute to the development of aortic and mitral valve diseases through the activation of AGK."

Journal • Cardiovascular • Fibrosis • Heart Failure • Immunology • AGK

Drug Repurposing Against Cestode Fatty Acid Binding Proteins Through Integrated Virtual Screening and In Vitro Validation. (PubMed, ChemMedChem) - "Four compounds-hydrochlorothiazide, naratriptan, fenticonazole, and montelukast-were selected for experimental validation, prioritizing repurposing candidates. Fluorescence displacement assays confirmed that hydrochlorothiazide binds to three cestode FABPs (EgFABP1, EmFABP1, and EmFABP3), validating the predictive performance of the computational workflow. These findings support the value of parallel in silico screening strategies and drug repurposing approaches for the discovery of new therapeutic candidates against NTD."

Journal • Preclinical • Infectious Disease • Metabolic Disorders • FABP1 • FABP3

The impact of ubrogepant on the use of other migraine acute treatments, opioid discontinuation, and healthcare utilization: Results from a pre-post opioid subcohort analysis (AHS 2026) - "Acute medications other than ubrogepant included acetaminophen, almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergotamine, ergotamine, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, metharbital, pentobarbital, phenobarbital, secobarbital, talbutal, barbital, codeine, hydrocodone, meperidine, morphine, oxycodone, propoxyphene, tramadol, aspirin, bromfenac, celecoxib, diclofenac, diflunisal, esomeprazole, etodolac, famotidine, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, lasmiditan, Zavegepant, and Rimegepant (<15 pills). Opioid use included acetaminophen/tramadol, oxymorphone, levorphanol, buprenorphine/naloxone, meperidine, morphine, oxycodone, codeine, methadone, oxycodone, hydromorphone, butorphanol, and tapentadol... In patients with a history of opioid use,..."

HEOR • CNS Disorders • Migraine • Pain

Spoken language and limited english proficiency as a barrier to care for the acute treatment of migraine: Results from a cross-institutional electronic health record (AHS 2026) - "Patients who spoke 24/28 (86%) of the non-English languages had an increased OR for receiving sumatriptan and they broadly had lower ORs for rizatriptan, eletriptan, zolmitriptan, naratriptan, rimegepant, and ubrogepant. Spoken language is an underexplored barrier to care in headache medicine. Our study demonstrates that patients who do not speak English often have lower rates of being prescribed acute medications for migraine overall and particularly for non-sumatriptan acute medications. Limited English proficiency remains an important social determinant of health, including accessing migraine medications."

Clinical • CNS Disorders • Migraine • Pain

Integrating gepants into clinical practice for the acute treatment of migraine. (PubMed, Headache) - "Key advantages of gepants include their favorable tolerability, efficacy for the acute treatment of both the prodromal/premonitory phase (ubrogepant) and the headache phase of migraine (ubrogepant, rimegepant, zavegepant), lack of cardiovascular contraindications, and lack of association with medication-overuse headache. Disadvantages include limitations due to cost and access and CYP3A4 drug interactions for most gepants. Together, the advantages may help to optimize patient care and lead to better persistence and effectiveness in a real-world setting. Head-to-head studies are needed to clarify the comparative effectiveness of triptans and gepants."

Journal • Review • Cardiovascular • CNS Disorders • Migraine • Pain • CYP3A4

Comparative analysis of efficacy between sumatriptan and naratriptan in the abortive treatment of migraine (EHF-EHC 2025) - "Sumatriptan and Naratriptan are both effective in the abortive treatment of oral migraine; however, they possess distinct characteristics. Therefore, factors such as time to pain relief, duration of effect, recurrence rate of attacks, and cardiovascular adverse effects should be considered. Thus, the choice between the two medications should be made based on the patient's profile and clinical needs for attack control, considering both efficacy and safety profile."

Clinical • Cardiovascular • CNS Disorders • Migraine • Pain

Peripheral nerve blocks for chronic migraine: A case report on long term improvement following repeat multi-site injections (ASRA-FALL 2025) - "The Patient: A 30-year-old woman with a 10-year history of chronic migraines Mild Daily, constant, waxiing-and-waning, left-sided periorbital pressure Moderate-Severe Weekly left-sided periorbital, occipital, and temporal pressure with and without aura Prior preventative therapies Topiramate, nortriptyline, duloxetine, propranolol, CGRP monoclonal antibodies (inject), Gepants (oral) Abortive therapies Rizatriptan, Naratriptan Intervention: The Blocks Targets Greater and lesser occipital, auriculotemporal, supraorbital, supratrochlear nerves—identified via anatomical landmarks Injectate 0.5% bupivacaine without steroid Frequency/ Duration Every 3 months since 2023 at an outside facility, continued at VMMC 1 Symptoms Changes Migraine Characteristics Baseline Pre-Block 1 month Post-Block 3 months Post-Block Mild Migraine Average pain score (/10) 4.5 None 2.5 Duration Constant None Constant Days free of MILD migraine (per month) 0 30 0 Moderate-Severe Migraine Average..."

Case report • Clinical • Anesthesia • CNS Disorders • Migraine • Pain

Characteristics and management of headache among psychiatric outpatients at a Japanese general hospital: A retrospective study with an exploratory CGRP case series. (PubMed, PCN Rep) - "At the agent level, acetaminophen (n = 38), loxoprofen (n = 33), zolmitriptan (n = 14), goreisan (n = 8), sumatriptan (n = 6), kakkonto (n = 6), diclofenac (n = 4), valproic acid (n = 4), and naratriptan (n = 3) were among the most frequently listed. CGRP-targeted therapy yielded headache relief even under psychiatric comorbidity, while psychiatric symptoms did not uniformly improve, underscoring the need for parallel mental-health interventions alongside headache-specific care. Strengthening cross-specialty pathways and early headache evaluation within psychiatry are warranted."

Journal • Retrospective data • Autism Spectrum Disorder • Bipolar Disorder • Cardiovascular • CNS Disorders • Depression • Genetic Disorders • Mental Retardation • Migraine • Pain • Post-traumatic Stress Disorder • Psychiatry • Rheumatology • Schizophrenia • Social Anxiety Disorder

A Pharmacovigilance Study from 2004 to 2024 Utilizing the FDA Adverse Event Reporting System (FAERS) Examines Ischemic Adverse Events Linked to Triptan Use in Migraine Therapy. (PubMed, J Pain Res) - "The report proportion varied among triptans, with naratriptan (12.23%) and almotriptan (12.15%) showing the highest rates, while sumatriptan (4.74%) had the lowest...Disproportionality analysis revealed significant signals for almotriptan (ROR=3.34), naratriptan (ROR=2.96), and rizatriptan (ROR=2.41), with almotriptan exhibiting the strongest association...Time-to-onset analysis showed frovatriptan had the earliest median onset (3.5 days), while almotriptan had the longest (284 days)...Clinicians should carefully evaluate cardiovascular risk factors before prescribing triptans and consider alternative treatments for susceptible individuals. Additional prospective studies are required to validate these findings."

Adverse events • Journal • Cardiovascular • CNS Disorders • Coronary Artery Disease • Ischemic stroke • Migraine • Myocardial Infarction • Pain

COMPARATIVE ANALYSIS OF THE EFFICACY BETWEEN SUMATRIPTAN AND NARATRIPTAN IN THE ABORTIVE TREATMENT OF MIGRAINE (WCN 2025) - ": Both SMT and NRT are effective abortive treatments with distinct pharmacodynamic profiles. NRT may offer superior tolerability and sustained efficacy in selected patients, supporting individualized therapeutic decisions."

Clinical • CNS Disorders • Migraine • Pain

The efficacy of various acute medicine for osmophobia, and characteristics in Japanese migraineurs. (IHC 2025) - "Triptans are effective compared to lasmiditan and NSAIDs as acute medicine. Conclusion The reasons sumatriptan and naratriptan are more effective might be because the effect is fast (sumatriptan includes nasal spray and subcutaneous injection), and the effect of naratriptan is long-acting. It remains to be seen how preventive medications including anti-CGRP monoclonal antibodies affect odor triggers and osmophobia."

Clinical • CNS Disorders • Migraine

Primary Headache Associated with Sexual Activity: Case Report and Diagnostic Approach (IHC 2025) - "Prophylactic treatment with indomethacin, naratriptana or ergotamine before 30 to 60 minutes intercourse has been effective. Other preemptive, for those cases of frequent and severe migraine attacks, beta-blockers or calcium channel blocker has been usually used. Conclusion The presented report provides evidence of a typical case of PHASA, showing good resolution with the interventions proposed by traditional literature."

Case report • Clinical • CNS Disorders • Migraine

Challenges and Clinical Practices in Managing Cluster Headache: Results from a Survey of Latin American Headache Specialists (IHC 2025) - "The survey explored demographic and geographic profiles, annual CH caseloads, use of transitional therapies (e.g., naratriptan), adherence to guideline-recommended treatments (e.g., oxygen and sumatriptan), diagnostic timelines, opioid use, professional engagement, and the presence of support systems for patients. There is an urgent need for educational initiatives, adherence to clinical guidelines, improved access to treatments like oxygen and sumatriptan, and stronger patient support. A unified regional strategy, enhanced professional development, and investment in advocacy are essential to improve care for cluster headache sufferers."

Clinical • Migraine

COMPARATIVE ANALYSIS OF THE EFFICACY BETWEEN SUMATRIPTAN AND NARATRIPTAN IN THE ABORTIVE TREATMENT OF MIGRAINE (IHC 2025) - "NRT may offer superior tolerability and sustained efficacy in selected patients. These insights support the need for individualized therapeutic strategies based on patient profile, clinical priorities, and cardiovascular risk."

Clinical • CNS Disorders • Migraine

Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system. (PubMed, PLoS One) - "Positive tinnitus signals were observed for several CGRP inhibitors, except eptinezumab and atogepant, and for all triptans except sumatriptan...However, intra-class analysis identified naratriptan, almotriptan, and frovatriptan as having notable tinnitus signals among triptans, while CGRP inhibitors did not exhibit strong signals for any specific drug. Using real-world data from FAERS and pharmacovigilance methods, this study identified tinnitus signals related to migraine treatments, particularly among certain triptans. These findings provide preliminary evidence for further investigation into the relationship between migraine medications and tinnitus."

Adverse events • Journal • CNS Disorders • Migraine • Otorhinolaryngology • Pain

The effect of selective adenosine A3 receptor (A3AR) agonism on migraine-like dural-responsive trigeminocervical neurons (AHS 2025) - "We tested the effects of two highly selective A3AR agonists (Cl-IB-MECA and MRS5980; 1 mg/kg each) comparing to naratriptan (3 mg/kg; positive control) or saline (vehicle control) and measured neuronal outcomes over 180 min... These data provide preclinical support that A3AR agonism modulates dural-responsive trigeminocervical neurons, inhibiting neuronal activity. It may therefore have a potential role in migraine-related mechanisms and provides strong support for A3AR as a novel target for therapeutic development. Further validation is necessary in models of trigeminovascular-neuronal sensitization to support these data and to dissect the potential role of adenosine-A3AR signaling in migraine pathogenesis."

CNS Disorders • Migraine • Neuralgia • Pain

Label-free morphology-based phenotypic analysis of spinal and bulbar muscular atrophy muscle cell models. (PubMed, Dis Model Mech) - "We then trained a predictive machine learning model to classify the drug responses, and it successfully discriminated between pioglitazone-type and naratriptan-type morphological profiles based on their morphological characteristics. Our morphology-based phenotypic analysis provides a noninvasive and efficient screening method to accelerate the development of therapeutics for SBMA."

Journal • CNS Disorders • Muscular Atrophy

Assessing the association between drug use and ischaemic colitis: a retrospective pharmacovigilance study using FDA Adverse Event data. (PubMed, BMJ Open) - "This study identified key drugs associated with ischaemic colitis, particularly alosetron, tegaserod, osmoprep, naratriptan and kayexalate. Notably, two-thirds of these drugs lacked ischaemic colitis warnings in their package inserts. These findings underscore the need for greater clinical vigilance, improved regulatory oversight and further research to clarify underlying mechanisms and support safer medication use."

Adverse events • Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology

The impact of headache specialist density and the introduction of gepants and lasmitidan on prescriptions for acute migraine treatments: a regression and interrupted time series analysis. (PubMed, Front Neurol) - "In our interrupted time-series analysis, the introduction of the gepants and lasmiditan was linked to decreases in triptan utilization, except for eletriptan which remained stable, and rizatriptan which rose at a slower rate...Our study suggests increased headache provider availability is associated with more prescriptions for naratriptan, eletriptan, and almotriptan. Additionally, the introduction of the gepants and lasmiditan broadly decreased the utilization of triptans. Critically, there was a strong association between a pharmaceutical company's, Pfizer, payments to physicians and utilization of their medication, rimegepant."

Journal • CNS Disorders • Migraine • Pain

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database. (PubMed, J Headache Pain) - "Analyses have demonstrated that AEs are present in a range of systems, including cardiac, nervous, gastrointestinal, and musculoskeletal disorders. It should be noted, however, that the incidence and signal intensity of these AEs vary depending on the specific drug in question. In clinical practice, the selection of an appropriate drug and the monitoring of AEs should be tailored to the individual patient's and specific characteristics."

Adverse events • Journal • Real-world • Real-world evidence • Retrospective data • CNS Disorders • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Migraine • Musculoskeletal Diseases • Pain • Pulmonary Disease

A Pilot Study on the Drug Price Revision Strategy in Japan: A Comparison Among Fiscal Years 2018, 2020, and 2022. (PubMed, Hosp Pharm) - "In FY2020, sumatriptan and eletriptan were cost-effective, and rizatriptan was extended-dominated; nevertheless, the other triptans were dominated by sumatriptan. In FY2022, naratriptan and eletriptan were cost-effective; however, the other triptans were dominated by naratriptan...The variations could be problematic because in Japan, formulary management of triptans, for example, those for migraine, may face revaluation every other year. Discussions regarding this issue will be further explored in the future."

Journal • CNS Disorders • Migraine • Pain

Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. (PubMed, BMJ) - "Overall, eletriptan, rizatriptan, sumatriptan, and zolmitriptan had the best profiles and they were more efficacious than the recently marketed drugs lasmiditan, rimegepant, and ubrogepant. Although cost effectiveness analyses are warranted and careful consideration should be given to patients with a high risk cardiovascular profile, the most effective triptans should be considered as preferred acute treatment for migraine and included in the WHO List of Essential Medicines to promote global accessibility and uniform standards of care."

Clinical • Journal • Retrospective data • Review • Cardiovascular • CNS Disorders • Migraine • Pain